IMM2510+Chemo for 1L NSCLC: 1st Patient Enrolled in Phase Ib/II

文章预览

On January 13, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco", Stock Code: 01541.HK) announced that the Phase Ib/II clinical trial of its PD-L1xVEGF bispecific antibody IMM2510 combined with chemotherapy for the treatment of first-line non-small cell lung cancer (NSCLC) has completed the enrollment of its first patient. This marks another significant milestone in the rapid clinical advancement of IMM2510. Following a safety run-in, the Company plans to enroll first-line patients in the aforesaid clinical trial and anticipates releasing initial clinical data, including data from the first-line patients with NSCLC, as early as the second half of 2025. Results from the dose-escalation stage of the Phase I study of IMM2510 have demonstrated promising therapeutic signals: partial tumor response (PR) was observed in several patients with advanced solid tumors who had failed multiple lines of treatment. As of December 31, 2024, over 100 patients have been enr ………………………………